Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Chikungunya
Fierce Pharma
Bavarian Nordic's $160M PRV price reflects new realities
The value of PRVs appears to be on the rise as concerns mount over declining supplies following the sunset of the rare pediatric disease PRV program.
Angus Liu
Jun 18, 2025 11:47am
Valneva sells priority review voucher for $103M, R&D to benefit
Feb 5, 2024 9:15am
FDA delays decision on Valneva's chikungunya vaccine by 3 months
Aug 14, 2023 6:00am
Bavarian Nordic goes 2 for 2 in key chikungunya vaccine trials
Aug 7, 2023 5:40am
Bavarian Nordic chikungunya vaccine hits primary goal in phase 3
Jun 20, 2023 9:00am
Durability of Valneva’s chikungunya vaccine holds up in phase 3
Mar 8, 2022 9:00am
